

ECS Botanics Holdings Ltd (ASX:ECS)



ASX Announcement

22 June 2026

ECS Launches First Australian-Grown Terphogz Product

Highlights:

- ECS launches Gelonoidz #20, the first Australian-grown Terphogz product, with commercial sales commencing today
- Premium dried flower product featuring a 23% THC label claim and total terpenes of approximately 2.8%
- Developed through ECS's phenotype selection program using licensed Terphogz genetics and endorsed by Terphogz following review of the selected phenotype and flower quality
- Initial commercial production completed, with further cultivation underway to support both domestic and export market opportunities
- Launch forms part of ECS's strategy to expand its premium branded portfolio, with up to three Terphogz cultivars expected during FY27

ECS Botanics Holdings Ltd (ASX: ECS) ("ECS" or the "Company"), a leading Australian medicinal cannabis cultivator and manufacturer, is pleased to announce the launch of Gelonoidz #20, the first Australian-grown Terphogz product. This marks an important milestone in the Company's strategy to commercialise globally recognised cannabis genetics through its Australian cultivation platform.

Gelonoidz #20 is a premium dried flower product with a 23% THC label claim and total terpene content of approximately 2.8%. The cultivar was selected following an extensive phenotype selection program conducted by ECS using licensed Terphogz genetics, with Gelonoidz #20 chosen for its terpene profile, flower quality and suitability for the premium medicinal cannabis segment.

The selected phenotype and finished flower quality were reviewed and endorsed by Terphogz, which provided positive feedback on the outcome of ECS's cultivation and phenotype selection program. ECS believes Gelonoidz #20 represents the highest quality flower the Company has produced to date and demonstrates the capability of its mixed-light Australian cultivation platform to consistently produce premium flower at commercial scale using globally recognised genetics.

Commercial sales of Gelonoidz #20 will commence on 22 June 2026 through the Company's established distribution channels, supported by ECS's Medical Science Liaison team through engagement with



prescribers. Initial commercial production has been completed, with further cultivation underway to support both domestic demand and future export opportunities.

The launch represents the first step in ECS's refreshed Terphogz strategy and is expected to be followed by the release of additional Terphogz cultivars during FY27. ECS currently expects up to three Terphogz cultivars to be available during the year, further expanding the Company's premium branded product portfolio.

ECS Botanic's Managing Director, Nan-Maree Schoerie, commented:

"Gelonoizd #20 is an important milestone for ECS. It demonstrates the quality that can be achieved when globally recognised genetics are combined with Australian cultivation expertise and our mixed-light production platform."

"Our decision to cultivate Terphogz genetics through ECS's own cultivation platform has allowed us to fully control quality, consistency and phenotype selection. The result is what we believe to be the highest quality flower ECS has produced to date and a product that is well positioned within the premium segment."

"We are pleased that Terphogz has endorsed the outcome of the program and the quality of the finished flower. Importantly, Gelonoizd #20 is only the first of several Terphogz cultivars expected to launch during FY27 as we continue to build a differentiated portfolio of premium, traceable Australian-grown medicines under recognised genetics brands."

About Terphogz™

Terphogz™ is a cannabis genetics and breeding group from Mendocino County, California, recognised by consumers internationally for its terpene-rich cultivars and The Original Z™ genetics. ECS holds licensing rights to cultivate, market and distribute Terphogz products in selected territories under its agreement with Terphogz.

Authorised for release by Nan-Maree Schoerie, Managing Director

-ENDS-

Investors and Media

Tim Dohrmann, NWR Communications

P: +61 468 420 846

E: tim@nwrcommunications.com.au

About ECS Botanic Holdings Ltd

ECS Botanic Holdings Ltd (ASX: ECS) is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EU agencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.